NCT02120157 - Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2015

Primary Completion Date

June 15, 2018

Study Completion Date

October 1, 2020

Conditions

Myeloablative ConditioningHLA-mismatched Bone Marrow TransplantationGraft SurvivalTransplantation, Bone Marrow

Interventions

DRUG

Cyclophosphamide

Chemotherapy administration

RADIATION

TBI

Radiation Therapy

DRUG

Busulfan

Chemotherapy Administered

OTHER

Unmanipulated Bone Marrow

Bone Marrow Transplant

DRUG

Tacrolimus

Immunosuppressive Drug Administered

DRUG

Mycophenolate mofetil

Immunosuppressive Drug Administered

Trial Locations (9)

19803

Nemours Alfred I. DuPont Hospital for Children, Wilmington

21287

Johns Hopkins Hospital, Baltimore

28203

Levine Cancer Center, Charlotte

29423

Medical University of South Carolina, Charleston

33701

All Children's Hospital Johns Hopkins Medicine, St. Petersburg

63110

Washington University in St. Louis, St Louis

80045

Children's Hospital of Colorado, Aurora

V6H 3V4

British Columbia Children's Hospital, Vancouver

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER